Liposarcoma

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

CDK4, FRS2, FASN, YEATS4, NF1, CDK6, IL22, FUS, TP53, MDM2, DDIT3, PPARG, HMGA2, CD6, CDKN2A, MIR155, TBC1D9, TARDBP, PLIN1, CD274, ABCB1, MIR193B, EWSR1, MXLPO, HCCS, FOLH1, PNPLA2, TSN, NANS, PIK3CA, MBTPS2, HSP90AA1, AURKA, AKT1, CRK, SREBF1, PTEN, TERT, CTAG1A, CAVIN1, CTAG1B, TSPAN31, MAP3K5, RET, CAVIN2, KL, EIF2S2, DYRK1B, TAF15, PER2, AIMP2, MBTPS1, TRIO, PAX8, ZIC1, XPO1, VIM, GPNMB, TOP2A, TIMP4, TIMP1, THRSP, TCN1, TAL1, TAF12, STC1, STAT6, STAT3, GRAP2, A2M, IFI44, MIR143, PNPLA3, CRISPLD2, IMMP2L, DNER, MYOCD, SPPL3, PDIK1L, CENPV, MIR144, AHSA1, MIR145, MIR214, MIR25, MIR26A2, MIR451A, BCRP1, CCDC180, LOC107228383, PRUNE1, TP53INP2, MEPE, HEATR3, IGF2BP2, SPIN1, SOX21, RASSF1, ATF6, CDK19, TAB2, SOX10, SMUG1, RNF19A, WWTR1, DNM3, POLDIP2, FGF21, FOXP1, EML4, G0S2, SRC, PTK2, SOX2, FGFR1, HBEGF, E2F1, E2F4, EGFR, EIF2S1, EIF2S3, EIF4E, EPAS1, GDNF, CTNNB1, GH1, GHR, GNAS, GPS2, HMBS, HMGB2, HMGA1, HOXA5, DAXX, CSF1R, HTC2, CAPN3, PARP1, APC, APCS, STS, ATP2A2, CCND1, BCL2, CALR, CASP10, MAPK14, CAV2, CCK, CD38, CDK11B, CEBPB, CHEK1, KLF6, CPM, HOXC13, IGF1, SOD1, MAPK1, PDGFRB, PER1, PIK3CB, PIK3CD, PIK3CG, PLAG1, PLK1, PML, PSMD8, OSBP, PLIN2, PTK7, PTX3, RASA2, RPS14, S100A4, SBF1, SDC1, PDGFRA, DDR2, IGF2, LEPR, IGFBP5, IL6, JUN, KCNH1, KIT, LBR, LDLR, LEP, LPP, YBX1, MAZ, MDM4, MLH1, MMP2, MSH2, MSRA, MYC, NAB2, H3P10

Drugs

(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate, (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide mono(4-methylbenzenesulfonate) monohydrate, 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide, 18-(p-(, 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide, 7-ethyl-10-hydroxy-camptothecin, Anlotinib, Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4, Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1, Brostallicin, Camsirubicin, Crenolanib besylate, Deforolimus, Doxorubicin hydrochloride (liposomal) ( DOXIL ), Doxorubicin(6-maleimidocaproyl)hydrazone, Fenretinide, Fibromun, Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor, Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein (NY-ESO-1), Human/murine chimeric monoclonal antibody against endoglin, Larotrectinib ( VITRAKVI ), Mammalian target of rapamcyin (mTOR) inhibitor, N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide, Olaratumab ( LARTRUVO ), Ombrabulin, Paclitaxel ( TAXOL ), Palifosfamide, Propranolol hydrochloride ( HEMANGEOL ), Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein, Trabectedin ( YONDELIS ), Vinorelbine tartrate, Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10

Interested in hearing about new therapies?

Liposarcoma is a tumor that arises from fat tissue. This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. The World Health Organization classification of soft tissue tumors recognizes 5 types of liposarcomas: Well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. Most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. Although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation.